NICE approves Lynparza plus Avastin via Cancer Drugs Fund
Genomic HRD testing to be launched to support the introduction of this treatment regimen
Read More
Tag: Avastin
Roche’s Tecentriq/Avastin combo improves survival in liver cancer
Updated analysis is from the Phase III IMbrave150 study
Read More
Tecentriq misses mark in ovarian cancer trial
The drug did not extend progression-free survival in patients with newly diagnosed advanced stage ovarian cancer
Read More
Roche’s Tecentriq/Avastin combo wins US approval
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer
Read More
Tecentriq, Avastin combo trumps Nexavar in liver cancer
Hepatocellular carcinoma is a major cause of cancer deaths worldwide, affecting over 750,000 people every year.
Read More
MHRA clarifies position on off-label Avastin
Roche’s drug has been used for years to treat wet AMD, an indication for which it is not specifically licensed
Read More
NICE recommends Roche’s Tecentriq for metastatic NSCLC
The recommendation is for the drug in combination with Avastin (bevacizumab), carboplatin and paclitaxel.
Read More
Pfizer’s biosimilar Zirabev wins EU approval
Pfizer has announced European approval of its Avastin biosimilar Zirabev.
Read More
Early access to Tecentriq combination granted through EAMS
UK patients with a form of advanced lung cancer will soon be able to access the immunotherapy drug Tecentriq in combination with Avastin, carboplatin and paclitaxel through the Early Access to Medicines Scheme (EAMS).
Read More
High Court rejects Novartis, Bayer’s bid to outlaw off-label Avastin
Bayer and Novartis have lost a landmark case in the UK seeking to prevent the off-label use of Roche’s Avastin to treat wet AMD, a leading cause of sight loss in the elderly.
Read More
FDA extends review time for Roche’s Tecentriq/Avastin combo
US regulators have extended the review period for Roche’s application to market Tecentriq in combination with Avastin, carboplatin and paclitaxel for first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).
Read More
First-line use of Roche’s Tecentriq given priority review
US regulators are undertaking a priority review of Roche unit Genentech’s PD-L1 inhibitor Tecentriq, in combination with Avastin and standard chemotherapy for some patients with lung cancer.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
